Shanghai Mengkai Biotechnology

Shanghai Mengkai Biotechnology is a specialized biotechnology company focused on the frontier of targeted protein degradation (TPD). Based in Shanghai's Zhangjiang Hi-Tech Park, the company has developed a robust platform for the discovery of novel E3 ligase ligands and the design of Proteolysis Targeting Chimera (PROTAC) and molecular glue therapeutics. Their technological core involves high-throughput screening and medicinal chemistry aimed at expanding the toolkit of E3 ligases available for drug development beyond the industry-standard CRBN and VHL binders. Mengkai Biotech provides both contract research services to global partners and pursues internal drug discovery programs. The company's primary therapeutic focus areas include oncology and inflammatory diseases where traditional small molecule inhibitors have faced limitations.